Elsevier

Neuromuscular Disorders

Volume 22, Supplement 3, 1 December 2012, Pages S203-S207
Neuromuscular Disorders

Fatigue in immune-mediated neuropathies

https://doi.org/10.1016/j.nmd.2012.10.014Get rights and content

Abstract

Fatigue, a highly debilitating symptom, is reported in most patients with immune-mediated neuropathies, particularly in Guillain–Barré syndrome, chronic immune-mediated demyelinating polyradiculoneuropathy, monoclonal gammopathy of undetermined significance related polyneuropathy, and multifocal motor neuropathy. Aspects like the degree of known fatigue in these disorders, its impact on daily functioning and quality of life, the suggested underlying mechanisms, and possible therapeutic interventions for fatigue will be addressed in this review.

Introduction

Immune-mediated neuropathies include Guillain–Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), polyneuropathy associated with monoclonal gammopathy of undetermined significance (MGUSP), and multifocal motor neuropathy (MMN). Electrophysiological examination in these patients generally reveals features of a demyelinating polyneuropathy, although a subgroup of GBS patients may have predominantly axonal features (acute motor axonal neuropathy (AMAN)). Diagnostic criteria for all these neuropathies have been formulated [1], [2], [3], [4]. From a clinical point of view there is increasing evidence that these illnesses represent part of a continuum, mainly separated by the location and extent of motor and/or sensory deficit, their evolution over time, and their response to treatment [1], [2], [3], [4]. However, despite being potentially treatable, particularly in GBS, CIDP, and MMN, studies on residual deficits in these conditions have demonstrated deficits in daily and social activities and decrement in quality of life expectations [5], [6], [7], [8], [9]. Moreover, some reports have addressed less tangible complaints in these conditions like being fatigued as one of the most important causes of dysfunctioning [7], [9], [10], [11], [12], [13], [14], [15]. Since attention in these illnesses is primarily directed towards weakness and sensory disturbances, it is suggested that fatigue may have been under-recognized for years by neurologists and rehabilitation physicians.

The pathogenesis of fatigue in neuromuscular diseases is unknown, but is believed to be multifactorial and may be caused by peripheral and central processes [16], [17], [18]. This review will be highlighting the known literature on fatigue in immune-mediated disorders, particularly focusing on GBS, CIDP, MGUSP, and MMN. The impact of fatigue on daily functionality and quality of life, the suggested underlying mechanisms, and possible therapeutic interventions will be addressed as well. Finally, unanswered questions for future studies in this field will be highlighted.

Section snippets

Papers addressing fatigue in immune-mediated neuropathies

An initial paper in the late eighties briefly addressed fatigue as a residual complaint in a limited number of GBS cases. The presence of fatigue was compared between patients with neuromuscular disorders (myasthenia gravis, GBS (n = 3), myopathies, metabolic muscle disorders) versus two other groups of patients (group 1: chronic fatigue syndrome not otherwise explained; group 2: patients with major depression) using a fatigue symptoms assessment that comprises questions to determine physical and

Assessment of fatigue

Over 30 scales have been developed attempting to measure the nature, severity and impact of fatigue in a wide range of clinical populations [30]. These outcome measures vary greatly in their content and in how well they have been evaluated. The most widely used outcome measure in immune-mediated neuropathies is the unidimensional Fatigue Severity Scale (FSS) [9], [19]. This scale has demonstrated to be very brief with good scientific soundness (validity and reliability scores) [9]. However,

Impact on daily functioning and quality of life

Contradictory findings have been published regarding the impact of fatigue on disability and quality of life expectations in patients with immune-mediated neuropathies. Fatigue did not show any correlation with clinical features like general weakness, sensory deficit, duration of illness, age, or type of diagnosis in patients with GBS, CIDP, and MGUSP. In essence, the severity of fatigue was equivalent between patients with normal strength or sensory deficit and those having physical deficits

Therapeutic options of fatigue in immune-mediated neuropathies

In immune-mediated neuropathies, physical training seemed to have a positive effect on reducing fatigue [13], [25]. In patients recovered from GBS and in patients with well-established ongoing therapy suffering from CIDP with severely reported fatigue, implementation of an exercise programs demonstrated a substantial reduction of 20% of self-reported fatigue [13], [17]. This improvement had been maintained at 2-year follow-up. However, the underlying mechanism for this positive effect has not

Conclusion

Fatigue is a highly prevalent and disabling symptom in immune-mediated neuropathies with severe impact on daily living, social functioning and quality of life. The aetiology of fatigue in these disorders, like in other illnesses, has not been elucidated yet and is considered to be multi-factorial. Future studies are warranted to focus on the underlying mechanisms leading to fatigue, which could provide an insight to a better therapeutic approach, hereby improving the well being of patients with

Conflicts of interest

The authors have nothing to disclose.

References (45)

  • European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic...
  • I.S. Merkies et al.

    Quality of life complements traditional outcome measures in immune-mediated polyneuropathies

    Neurology

    (2002)
  • I.S. Merkies et al.

    Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study

    J Peripher Nerv Syst

    (2010)
  • R.A. Bernsen et al.

    Residual health status after Guillain–Barre syndrome

    J Neurol Neurosurg Psychiatry

    (1997)
  • I.S. Merkies et al.

    Connecting impairment, disability, and handicap in immune mediated polyneuropathies

    J Neurol Neurosurg Psychiatry

    (2003)
  • I.S. Merkies et al.

    Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) group

    Neurology

    (1999)
  • S. Wessely et al.

    Fatigue syndromes: a comparison of chronic “postviral” fatigue with neuromuscular and affective disorders

    J Neurol Neurosurg Psychiatry

    (1989)
  • R.J. Gregory

    Understanding and coping with neurological impairment

    Rehabil Nurs

    (1995)
  • F. Khan et al.

    Factors associated with long-term functional outcomes and psychological sequelae in Guillain–Barre syndrome

    J Neurol

    (2010)
  • M.P. Garssen et al.

    Physical training and fatigue, fitness, and quality of life in Guillain–Barre syndrome and CIDP

    Neurology

    (2004)
  • P.G. Erdmann et al.

    Functioning of patients with multifocal motor neuropathy

    J Peripher Nerv Syst

    (2010)
  • T. Kyriakides et al.

    Sleep hypoventilation syndrome and respiratory failure due to multifocal motor neuropathy with conduction block

    Muscle Nerve

    (2011)
  • Cited by (20)

    • Guillain-Barré syndrome

      2020, Dysimmune Neuropathies
    • Sleep and Neuromuscular Disease

      2017, Sleep and Neurologic Disease
    • Guillain-Barré syndrome

      2016, The Lancet
      Citation Excerpt :

      About 20% of patients with Guillain-Barré syndrome cannot walk unaided 6 months after onset. Most patients have residual pain and fatigue, which can in part be attributed to persistent axonal loss.98,99 Many patients have to change their work and daily activities, even after reaching a good functional level.75,100

    • Vitamin D deficiency in patients with primary immune-mediated peripheral neuropathies

      2014, Journal of the Neurological Sciences
      Citation Excerpt :

      Electrophysiological examination aids in the diagnosis of either a primarily demyelinating peripheral neuropathy or a mainly axonal neuropathy and defined diagnostic criteria govern these conditions [1]. Although these disorders are separated by their location in the peripheral nervous system and extent of motor and/or sensory deficits, they are more or less considered representative of a continuous disease spectrum [2]. Up-regulation of proinflammatory Th1 cytokines in the early course of GBS may be associated with immune-mediated disease progression through neuronal inflammation [3].

    • Increased cerebrospinal fluid protein and motor conduction studies as prognostic markers of outcome and nerve ultrasound changes in Guillain-Barré syndrome

      2014, Journal of the Neurological Sciences
      Citation Excerpt :

      A possible explanation for this residual impairment in GBS-a group could be derived from the fact that axonal loss leads to insufficient reinnervation and permanent muscle weakness. On the other hand, no significant changes were documented in the R-FSS score between the two groups (p = 0.018), showing that fatigue may be independent from axonal loss, despite having a significant impact on quality of life [14,23]. Concerning the nerve ultrasound findings, the GBS-a showed significantly lower CSA values of the median and ulnar nerve in upper arm compared to the GBS-d group (p < 0.001).

    • Three-Year Follow-Up Study in Patients with Guillain-Barré Syndrome

      2018, Canadian Journal of Neurological Sciences
    View all citing articles on Scopus
    View full text